Sterile injectables require sterility testing, endotoxin testing, and stability data appropriate to the route
It works at the tissue signaling level, which means it supports and amplifies other aesthetic and regenerative treatments rather than replacing them
Long-term evidence beyond 24 weeks is limited
KPV enters cells via a transporter that is upregulated in inflamed tissues, providing targeted delivery to areas of active inflammation
Epithelial cell protection from NSAIDs and ethanol, mucosal barrier integrity maintenance, anastomosis and fistula healing models (colo-cutaneous, recto-vaginal), ulcer healing mechanisms
Receptor Activity and Approval Status Is petrelintide a selective AMY1 agonist